Immunocore Holdings Plc · NASDAQ:IMCR
Immunocore — Q2 2026 Earnings Presentation
28 slides from Immunocore's earnings presentation, Aug 6, 2026
Slide 1: 2Q & 1H 2026 Financial Results & Business Update
Transformative immunomodulating medicines for patients 2Q & 1H 2026 Financial Results & Business Update 1
Slide 2: Forward Looking Statements
Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “aim”, “continue”, “target” and simila
Slide 3: Agenda
Agenda Advancing our strategic pillars Bahija Jallal, CEO KIMMTRAK growth opportunities Ralph Torbay, Chief Commercial Officer Pipeline update Mohammed Dar, Chief Medical Officer 2Q & 1H 2026 financial results Travis Coy, CFO & Head of Corporate Development Delivering on our promise Bahija Jallal, C
Slide 4: Radically improve outcomes with immunomodulating medicines
We want to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines 4
Slide 5: Near and long-term growth potential across strategic priorities
Near and long-term growth potential across strategic priorities Multiple catalysts expected to support value creation 1 Grow KIMMTRAK and prepare for potential new melanoma indications • $223M 1H 2026 net sales • 5-year OS for KIMMTRAK – doubling likelihood of being alive at 5 years • 3 Phase 3 mela
Slide 6: KIMMTRAK growth opportunities
KIMMTRAK growth opportunities Ralph Torbay Chief Commercial Officer 6
Slide 7: KIMMTRAK is the global standard of care in 1L mUM
KIMMTRAK is the global standard of care in 1L mUM1 16% year-over-year growth in 1H 2026 $223M 1H 2026 net sales >30 launched countries Continuing to demonstrate long term OS benefit $116M Median OS of 28 months ≥70% Q2 2026 net sales Most recent real-world data (150 patients)4 penetration in all maj
Slide 8: KIMMTRAK doubled likelihood of patients being alive at 5 years
KIMMTRAK doubled likelihood of patients being alive at 5 years Longest OS follow-up ever reported in a randomized metastatic uveal melanoma trial 16% OS rate on tebentafusp compared with 8% for investigator’s Tebentafusp Investigator s Choice choice (IC) 1.0 Median overall survival (95 CI • 44% only
Slide 9: KIMMTRAK has the potential to benefit up to 6K patients per year
KIMMTRAK has the potential to benefit up to 6K patients per year Large opportunities ahead Rare gp100+ tumors <100* Investigator led Up to Adjuvant uveal ATOM Phase 3 6,000* ~1.2K* melanoma 2028+1 patients 2L+ advanced Up to TEBE-AM Phase 3 cutaneous melanoma 4K* 20261 ~1K* APPROVED in 2022 Metastat
Slide 10: Pipeline update
Pipeline update Mohammed Dar Chief Medical Officer 10
Slide 11: Prepare for potential new melanoma indications
Prepare for potential new melanoma indications 11
Slide 12: Significant unmet need in 2L+ cutaneous melanoma
Significant unmet need in 2L+ cutaneous melanoma* Limited treatment options available for post-PD1 population PD-1 ± additional checkpoint (CTLA- Historical 1-year overall survival in 1L BRAF/MEKi 4 or LAG-3) 2L+ post anti-PD-1 population is ~55%1 BRAF/MEKi Opportunity for first ever approved PD-1 ±
Slide 13: TEBE-AM: The most advanced Phase 3 in 2L+ with OS endpoint
TEBE-AM: The most advanced Phase 3 in 2L+ with OS endpoint Enrollment nearing the target of 540 patients – Topline data as early as end of 2026 Phase 3 in 2L+ cutaneous melanoma Promising Phase 1/2 data sets in 2L+ cutaneous melanoma1 Design Endpoint KIMMTRAK N=180 75% KIMMTRAK + anti-PD-1 N=180 Ove
Slide 14: ATOM: The only active Phase 3 trial in adjuvant uveal melanoma
ATOM: The only active Phase 3 trial in adjuvant uveal melanoma Opportunity to impact disease at earlier timepoint | Now enrolling in the US Unmet need Phase 3 in high-risk adjuvant melanoma HLA-A02+ adjuvant uveal melanoma market1 Design Endpoint Primary Local Therapy Adjuvant Therapy KIMMTRAK N = 1
Slide 15: PRISM-MEL-301: PRAME Phase 3 trial in 1L cutaneous melanoma
PRISM-MEL-301: PRAME Phase 3 trial in 1L cutaneous melanoma Global randomization ongoing Unmet need Phase 3 Trial Design HLA-A02+ 1L cutaneous melanoma market Design Key endpoints 1L Brenetafusp + N=325 nivolumab1 • Primary: PFS by BICR BRAFwt • Secondary: OS, ORR ~55% PD-1 ± CPI • Exploratory: ctDN
Slide 16: Multiple lines of evidence support 1L Phase 3 trial of brene + nivo
Multiple lines of evidence supports 1L Phase 3 trial of brene + nivo Comparison to nivolumab and relatlimab + nivolumab 2L+ 1L mOS 4.4m 15.7m 17.1m 14.3m - mPFS 4.6m 10.2m 6m-OS ~78% 75% 75% 87% 87% 12m-OS ~55% 60% 60% 57% - ? 67% 60% 17% 49% 52% 47% DCR 12% 38% 40% 43% 27% 9% 33% PR/CR 10% 50% 40%
Slide 17: Expand beyond melanoma into other tumor types
Expand beyond melanoma into other tumor types 17
Slide 18: Building our second product franchise
Building our second product franchise Translating data between brenetafusp and PRAME-HLE provides path for next steps Brenetafusp Ph1/2 data support Data in 2026 will guide Phase 3 PRISM-MEL-301 in 1L CM next steps Ovarian – PROC/PSOC Melanoma Chemo & bevacizumab Monotherapy & PD-1 combo combination
Slide 19: Realize growth opportunities beyond oncology
Realize growth opportunities beyond oncology
Slide 20: HIV initial Phase 1 data demonstrated delayed viral rebound
HIV initial Phase 1 data demonstrated delayed viral rebound Well tolerated with dose dependent antiviral effect 15 / 30 / 60 mcg 20 / 40 / 120 mcg 20 / 40 / 300 mcg 10 8 10 8 Plasma viremia (copies/ml) Plasma viremia (copies/ml) 10 8 Plasma viremia (copies/ml) 5 evaluable ATI extended 10 7 10 7 10 7
Slide 21: Phase 1 trial with IMC-S118AI in type 1 diabetes
Phase 1 trial with IMC-S118AI in type 1 diabetes (T1D) First tissue-specific autoimmune candidate to enter the clinic in coming weeks Recently published data demonstrated in live human pancreas tissue slices, including from a recent-onset type 1 diabetes donor, that IMC-S118AI: • selectively binds t
Slide 22: Leading bispecific TCR pipeline
Leading bispecific TCR pipeline Candidate Target (HLA type) Indication Pre IND Phase 1 Phase 2 Phase 3 Approved Metastatic uveal (ocular) melanoma (tebentafusp-tebn) gp100-A02 Adjuvant uveal (ocular) melanoma ATOM sponsored by 2L+ advanced cutaneous melanoma TEBE-AM 1L advanced cutaneous melanoma PR
Slide 23: 2Q & 1H 2026 financial results
2Q & 1H 2026 financial results Travis Coy Chief Financial Officer & Head of Corporate Development 23
Slide 24: 2Q 2026 & 1H 2026 GAAP Financials (unaudited)
2Q 2026 & 1H 2026 GAAP Financials (unaudited) (in millions, except per share data) % change % change Key Figures (in USD) 2Q 2026 2Q 2025 vs. 1H 2026 1H 2025 vs. prior year prior year KIMMTRAK net revenue (US) 74.9 64.1 17% 142.4 120.7 18% KIMMTRAK net revenue (Europe) 34.1 33.0 3% 68.5 65.8 4% Othe
Slide 25: Delivering on our promise
Delivering on our promise Bahija Jallal Chief Executive Officer 25
Slide 26: Near and long-term growth potential across strategic priorities
Near and long-term growth potential across strategic priorities Multiple catalysts expected to support value creation Grow KIMMTRAK and prepare for potential 1 new melanoma indications Expand beyond melanoma into other tumor 2 types 3 Realize growth opportunities beyond oncology $880M in cash & mark
Slide 27: Q&A Session
Q&A Session Bahija Jallal Travis Coy Mohammed Dar PhD MD Chief Executive Officer Chief Financial Officer and Head Chief Medical Officer of Corporate Development Ralph Torbay Mark Moyer John Goll Chief Commercial Officer Chief Regulatory and Quality Chief Accounting Officer Officer 27
Slide 28: Thank you
IMMUNOCORE Thank you